<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118518</url>
  </required_header>
  <id_info>
    <org_study_id>MDT16012AFS001</org_study_id>
    <nct_id>NCT03118518</nct_id>
  </id_info>
  <brief_title>STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>STOP AF First</acronym>
  <official_title>STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide data demonstrating the safety and effectiveness of the Arctic Front Advance™&#xD;
      Cardiac CryoAblation Catheter for the treatment of recurrent symptomatic paroxysmal atrial&#xD;
      fibrillation, without the requirement that the subjects be drug refractory.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with paroxysmal atrial fibrillation with no history of treatment with&#xD;
      anti-arrhythmic drugs are randomized 1:1 to either an anti-arrhythmic drug or pulmonary vein&#xD;
      isolation using the cryoballoon catheter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2017</start_date>
  <completion_date type="Actual">June 25, 2020</completion_date>
  <primary_completion_date type="Actual">June 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment Success at 12 Months After Antiarrhythmic Drug (AAD) Initiation or Ablation Utilizing the Arctic Front Advance™ Cardiac CryoAblation Catheter.</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Treatment success after AAD initiation (control arm) or pulmonary vein isolation ablation procedure utilizing the Arctic Front Advance™ Cardiac CryoAblation Catheter (treatment arm). Treatment success is the opposite of treatment failure. Treatment failure was defined as any of the following:&#xD;
Acute procedural failure (treatment arm only).&#xD;
Documented AF/AT/AFL on ambulatory monitoring/12-lead ECG after the 90-day post-ablation blanking period (treatment)/AAD optimization period (control arm). Minimum of 30 seconds on ambulatory monitoring or 10 seconds on 12-lead ECG.&#xD;
Any subsequent AF surgery or ablation in the left atrium.&#xD;
Any subsequent cardioversion after the 90-day post-ablation blanking period (treatment)/AAD optimization period (control arm).&#xD;
Class I or III antiarrhythmic drug (or sotalol) use after the 90-day blanking period (treatment arm only).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint - Rate of Composite List of Serious Adverse Events.</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Measured by rate of composite list of serious adverse events in cryoablation-treated as randomized arm.&#xD;
Includes:&#xD;
TIA within 7 days&#xD;
Cerebrovascular accident within 7 days&#xD;
Major bleed that requires transfusion or results in a 20% or greater fall in hematocrit (HCT) within 7 days&#xD;
Development of a significant pericardial effusion within 30 days. (One that results in hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1-cm or more pericardial effusion as documented by echocardiography).&#xD;
Symptomatic PV stenosis within 12 months; accompanied by one of the following: 50%-75% reduction in diameter of the pulmonary vein, with symptoms not explained by other conditions; OR &gt;75% reduction in diameter of the pulmonary vein&#xD;
MI within 7 days&#xD;
PNI unresolved at 12 months&#xD;
AE fistula within 12 months&#xD;
Major vascular complication that requires intervention, prolongs hospital stay, or requires hospital admission (within 7 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scores at Baseline Compared to 12 Months</measure>
    <time_frame>Baseline and 12 Months</time_frame>
    <description>There are two hypotheses tested in the objective, with separate hypothesis tests for (1) the difference in composite scores from the AFEQT questionnaire taken at baseline and 12 month visits, and (2) for the difference in composite scores for the EQ-5D questionnaire taken at baseline and 12-month visits.&#xD;
Composite AFEQT score is on a scale of zero to one hundred. Higher scores are better.&#xD;
Composite EQ-5D score is on a scale of zero to one. Higher scores are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Utilization</measure>
    <time_frame>Initial treatment through 12 months.</time_frame>
    <description>Compare health care utilization between the treatment and control arms. There are two hypotheses tested in the objective, with separate hypothesis tests for: (1) the rate of total health care utilization events (cardiovascular-related hospitalizations, emergency room visits, or unscheduled office visits) over 12 months shown as freedom from cardiovascular health care utilization by treatment arm, and (2) freedom from cardioversions (electrical or pharmacological) over 12 months by treatment arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Fibrillation New Onset</condition>
  <arm_group>
    <arm_group_label>Anti-arrhythmic drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Pulmonary vein isolation via ablation with cryoballoon catheter</description>
    <arm_group_label>Cryoablation</arm_group_label>
    <other_name>ArcticFront Advance Cardiac CryoAblation Catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drug</intervention_name>
    <description>Antiarrhythmic drug initiation</description>
    <arm_group_label>Anti-arrhythmic drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of symptomatic paroxysmal AF with the following documentation: (1)&#xD;
             physician's note indicating recurrent self- terminating AF or paroxysmal AF; and (2)&#xD;
             any ECG documented AF within 6 months prior to enrollment.&#xD;
&#xD;
          -  Age 18-80&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of AF treatment with class I or III antiarrhythmic drug, including sotalol,&#xD;
             with the intention to prevent an AF recurrence. However, patients pretreated with&#xD;
             above AAD for less than 7 days with the intention to convert an AF episode are&#xD;
             allowed.&#xD;
&#xD;
          -  Prior persistent AF (cardioversion after 48 hours or continuous AF that is sustained&#xD;
             &gt;7 days)&#xD;
&#xD;
          -  Left atrial diameter greater than 5.0 cm&#xD;
&#xD;
          -  Prior left atrial ablation or left atrial surgical procedure&#xD;
&#xD;
          -  Presence or likely implant of a permanent pacemaker, biventricular pacemaker, loop&#xD;
             recorder, or any type of implantable cardiac defibrillator (with or without&#xD;
             biventricular pacing function)&#xD;
&#xD;
          -  Body mass index (BMI) &gt;35 kg/m2&#xD;
&#xD;
          -  Presence of any pulmonary vein stents&#xD;
&#xD;
          -  Known presence of any pre-existing pulmonary vein stenosis&#xD;
&#xD;
          -  Pre-existing hemidiaphragmatic paralysis&#xD;
&#xD;
          -  Presence of any cardiac valve prosthesis&#xD;
&#xD;
          -  Moderate or severe mitral valve regurgitation or stenosis&#xD;
&#xD;
          -  Any cardiac surgery, myocardial infarction, percutaneous coronary intervention/&#xD;
             percutaneous transluminal coronary angioplasty or coronary artery stenting which&#xD;
             occurred during the 90 day interval preceding the date the subject signed the Informed&#xD;
             Consent Form&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  New York Heart Association (NYHA) class III or IV congestive heart failure and/or&#xD;
             known left ventricular ejection fraction (LVEF) less than 45%&#xD;
&#xD;
          -  Diagnosis of primary pulmonary hypertension&#xD;
&#xD;
          -  Rheumatic heart disease&#xD;
&#xD;
          -  Thrombocytosis, thrombocytopenia&#xD;
&#xD;
          -  Contraindication to anticoagulation therapy&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Cryoglobulinemia&#xD;
&#xD;
          -  Known reversible causes of AF, including but not limited to uncontrolled&#xD;
             hyperthyroidism, obstructive sleep apnea, and acute alcohol toxicity.&#xD;
&#xD;
          -  Any cerebral ischemic event (strokes or transient ischemic attacks) which occurred&#xD;
             during the 180 day interval preceding the date the subject signed the Informed Consent&#xD;
             Form, or any known unresolved complications from previous stroke/transient ischemic&#xD;
             attack&#xD;
&#xD;
          -  Existing thrombus&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patient with life expectancy that makes it unlikely 12 months of follow-up will be&#xD;
             completed.&#xD;
&#xD;
          -  Current or anticipated participation in any other clinical trial of a drug, device or&#xD;
             biologic during the duration of this study not pre-approved by Medtronic&#xD;
&#xD;
          -  Patients with contraindications to a Holter monitor&#xD;
&#xD;
          -  Unwilling or unable to comply fully with study procedures and follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oussama Wazni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gopi Dandamudi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Franciscan Heart &amp; Vascular Associates at St. Joseph</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Nissen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grandview Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alaska Heart Institute</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>50266-8209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Hospital Newport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-3017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Research Institute Inc</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308-4646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BayCare Medical Group Cardiology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellstar Research Institute</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krannert Institute of Cardiology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266-8209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Office of Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>50266-8209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southcoast Health System</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System - University Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>50266-8209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast Saint Josephs Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102-1062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryan Heart</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>07450-2726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450-2726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center, Inc.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112-4418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Saint Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Cardiovascular Services</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>50266-8209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <results_first_submitted>June 22, 2021</results_first_submitted>
  <results_first_submitted_qc>July 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2021</results_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Version 4</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03118518/Prot_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Version 5</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03118518/Prot_005.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Version 6</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03118518/Prot_006.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03118518/SAP_007.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first enrollment in the STOP AF First study occurred in the United States on 23-JUN-2017. The final enrollment occurred on 13-MAY-2019.</recruitment_details>
      <pre_assignment_details>Of 225 enrolled participants, 210 met inclusion criteria and were randomized to treatment. Of the 15 who exited prior to randomization: 11 did not meet inclusion/exclusion criteria, 2 withdrew, 1 was lost to follow-up and 1 had study enrollment close prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects Randomized to Cryoballoon Catheter Ablation</title>
          <description>Subjects Randomized to Cryoballoon Catheter Ablation.</description>
        </group>
        <group group_id="P2">
          <title>Subjects Randomized to Antiarrhythmic Drug Therapy</title>
          <description>Subjects Randomized to Antiarrhythmic Drug Therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subject Treated According to Randomization Assignment</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Exit after treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early Exit after randomization but prior to treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects Treated With Cryoballoon Catheter Ablation as Randomized</title>
          <description>Subjects Treated with Cryoballoon Catheter Ablation as Randomized.</description>
        </group>
        <group group_id="B2">
          <title>Subjects Treated With Antiarrhythmic Drug Initiation</title>
          <description>Subjects Treated with Antiarrhythmic Drug Initiation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="11.2"/>
                    <measurement group_id="B2" value="61.6" spread="11.2"/>
                    <measurement group_id="B3" value="61.0" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment Success at 12 Months After Antiarrhythmic Drug (AAD) Initiation or Ablation Utilizing the Arctic Front Advance™ Cardiac CryoAblation Catheter.</title>
        <description>Treatment success after AAD initiation (control arm) or pulmonary vein isolation ablation procedure utilizing the Arctic Front Advance™ Cardiac CryoAblation Catheter (treatment arm). Treatment success is the opposite of treatment failure. Treatment failure was defined as any of the following:&#xD;
Acute procedural failure (treatment arm only).&#xD;
Documented AF/AT/AFL on ambulatory monitoring/12-lead ECG after the 90-day post-ablation blanking period (treatment)/AAD optimization period (control arm). Minimum of 30 seconds on ambulatory monitoring or 10 seconds on 12-lead ECG.&#xD;
Any subsequent AF surgery or ablation in the left atrium.&#xD;
Any subsequent cardioversion after the 90-day post-ablation blanking period (treatment)/AAD optimization period (control arm).&#xD;
Class I or III antiarrhythmic drug (or sotalol) use after the 90-day blanking period (treatment arm only).</description>
        <time_frame>Randomization to 12 months</time_frame>
        <population>Subjects who were received the treatment they were randomized to (modified intent to treat).</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Treated With Cryoballoon Catheter Ablation as Randomized</title>
            <description>Subjects Treated with Cryoballoon Catheter Ablation as Randomized.</description>
          </group>
          <group group_id="O2">
            <title>Subjects Treated With Antiarrhythmic Drug Initiation</title>
            <description>Subjects Treated with Antiarrhythmic Drug Initiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Success at 12 Months After Antiarrhythmic Drug (AAD) Initiation or Ablation Utilizing the Arctic Front Advance™ Cardiac CryoAblation Catheter.</title>
          <description>Treatment success after AAD initiation (control arm) or pulmonary vein isolation ablation procedure utilizing the Arctic Front Advance™ Cardiac CryoAblation Catheter (treatment arm). Treatment success is the opposite of treatment failure. Treatment failure was defined as any of the following:&#xD;
Acute procedural failure (treatment arm only).&#xD;
Documented AF/AT/AFL on ambulatory monitoring/12-lead ECG after the 90-day post-ablation blanking period (treatment)/AAD optimization period (control arm). Minimum of 30 seconds on ambulatory monitoring or 10 seconds on 12-lead ECG.&#xD;
Any subsequent AF surgery or ablation in the left atrium.&#xD;
Any subsequent cardioversion after the 90-day post-ablation blanking period (treatment)/AAD optimization period (control arm).&#xD;
Class I or III antiarrhythmic drug (or sotalol) use after the 90-day blanking period (treatment arm only).</description>
          <population>Subjects who were received the treatment they were randomized to (modified intent to treat).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="64.0" upper_limit="81.2"/>
                    <measurement group_id="O2" value="45.0" lower_limit="34.6" upper_limit="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint - Rate of Composite List of Serious Adverse Events.</title>
        <description>Measured by rate of composite list of serious adverse events in cryoablation-treated as randomized arm.&#xD;
Includes:&#xD;
TIA within 7 days&#xD;
Cerebrovascular accident within 7 days&#xD;
Major bleed that requires transfusion or results in a 20% or greater fall in hematocrit (HCT) within 7 days&#xD;
Development of a significant pericardial effusion within 30 days. (One that results in hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1-cm or more pericardial effusion as documented by echocardiography).&#xD;
Symptomatic PV stenosis within 12 months; accompanied by one of the following: 50%-75% reduction in diameter of the pulmonary vein, with symptoms not explained by other conditions; OR &gt;75% reduction in diameter of the pulmonary vein&#xD;
MI within 7 days&#xD;
PNI unresolved at 12 months&#xD;
AE fistula within 12 months&#xD;
Major vascular complication that requires intervention, prolongs hospital stay, or requires hospital admission (within 7 days).</description>
        <time_frame>Randomization to 12 months</time_frame>
        <population>Subjects who were cryoablation-treated as randomized (as was pre-specified in both the protocol and Statistical Analysis Plan)</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Treated With Cryoballoon Catheter Ablation as Randomized</title>
            <description>Subjects Treated with Cryoballoon Catheter Ablation as Randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint - Rate of Composite List of Serious Adverse Events.</title>
          <description>Measured by rate of composite list of serious adverse events in cryoablation-treated as randomized arm.&#xD;
Includes:&#xD;
TIA within 7 days&#xD;
Cerebrovascular accident within 7 days&#xD;
Major bleed that requires transfusion or results in a 20% or greater fall in hematocrit (HCT) within 7 days&#xD;
Development of a significant pericardial effusion within 30 days. (One that results in hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1-cm or more pericardial effusion as documented by echocardiography).&#xD;
Symptomatic PV stenosis within 12 months; accompanied by one of the following: 50%-75% reduction in diameter of the pulmonary vein, with symptoms not explained by other conditions; OR &gt;75% reduction in diameter of the pulmonary vein&#xD;
MI within 7 days&#xD;
PNI unresolved at 12 months&#xD;
AE fistula within 12 months&#xD;
Major vascular complication that requires intervention, prolongs hospital stay, or requires hospital admission (within 7 days).</description>
          <population>Subjects who were cryoablation-treated as randomized (as was pre-specified in both the protocol and Statistical Analysis Plan)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="0.48" upper_limit="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Scores at Baseline Compared to 12 Months</title>
        <description>There are two hypotheses tested in the objective, with separate hypothesis tests for (1) the difference in composite scores from the AFEQT questionnaire taken at baseline and 12 month visits, and (2) for the difference in composite scores for the EQ-5D questionnaire taken at baseline and 12-month visits.&#xD;
Composite AFEQT score is on a scale of zero to one hundred. Higher scores are better.&#xD;
Composite EQ-5D score is on a scale of zero to one. Higher scores are better.</description>
        <time_frame>Baseline and 12 Months</time_frame>
        <population>Subjects treated with cryoballoon catheter ablation as randomized (as was pre-specified in both the protocol and Statistical Analysis Plan) and who had QOL score available at both baseline and 12 month time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Treated With Cryoballoon Catheter Ablation as Randomized</title>
            <description>Subjects Treated with Cryoballoon Catheter Ablation as Randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Scores at Baseline Compared to 12 Months</title>
          <description>There are two hypotheses tested in the objective, with separate hypothesis tests for (1) the difference in composite scores from the AFEQT questionnaire taken at baseline and 12 month visits, and (2) for the difference in composite scores for the EQ-5D questionnaire taken at baseline and 12-month visits.&#xD;
Composite AFEQT score is on a scale of zero to one hundred. Higher scores are better.&#xD;
Composite EQ-5D score is on a scale of zero to one. Higher scores are better.</description>
          <population>Subjects treated with cryoballoon catheter ablation as randomized (as was pre-specified in both the protocol and Statistical Analysis Plan) and who had QOL score available at both baseline and 12 month time points.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AFEQT composite score (change from baseline to 12 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="29.1" upper_limit="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite EQ-5D score (change from baseline to 12 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.01" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Utilization</title>
        <description>Compare health care utilization between the treatment and control arms. There are two hypotheses tested in the objective, with separate hypothesis tests for: (1) the rate of total health care utilization events (cardiovascular-related hospitalizations, emergency room visits, or unscheduled office visits) over 12 months shown as freedom from cardiovascular health care utilization by treatment arm, and (2) freedom from cardioversions (electrical or pharmacological) over 12 months by treatment arm.</description>
        <time_frame>Initial treatment through 12 months.</time_frame>
        <population>All subjects treated as randomized (mITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Treated With Cryoballoon Catheter Ablation as Randomized</title>
            <description>Subjects Treated with Cryoballoon Catheter Ablation as Randomized.</description>
          </group>
          <group group_id="O2">
            <title>Subjects Treated With Antiarrhythmic Drug Initiation</title>
            <description>Subjects Treated with Antiarrhythmic Drug Initiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Utilization</title>
          <description>Compare health care utilization between the treatment and control arms. There are two hypotheses tested in the objective, with separate hypothesis tests for: (1) the rate of total health care utilization events (cardiovascular-related hospitalizations, emergency room visits, or unscheduled office visits) over 12 months shown as freedom from cardiovascular health care utilization by treatment arm, and (2) freedom from cardioversions (electrical or pharmacological) over 12 months by treatment arm.</description>
          <population>All subjects treated as randomized (mITT).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Freedom from Cardiovascular health care utilization.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="60.0" upper_limit="77.8"/>
                    <measurement group_id="O2" value="53.5" lower_limit="42.8" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from Cardioversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="91.3" upper_limit="99.1"/>
                    <measurement group_id="O2" value="92.4" lower_limit="84.8" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During or after treatment initiation through study completion (12 months visit).</time_frame>
      <desc>Adverse events occurring during the study were continuously monitored and collected.&#xD;
The following adverse events were collected starting at the time subjects signed the Informed Consent Form through the duration of the subject's participation in the study:&#xD;
All procedure related AEs&#xD;
All cryoablation system related AEs&#xD;
All AAD related AEs&#xD;
All cardiovascular related AEs&#xD;
All Serious Adverse Events (SAEs), regardless of relatedness</desc>
      <group_list>
        <group group_id="E1">
          <title>Randomized and Treated With Cryoablation</title>
          <description>Subjects Treated with Cryoballoon Catheter Ablation as Randomized.</description>
        </group>
        <group group_id="E2">
          <title>Randomized and Treated With Antiarrhythmic Drugs</title>
          <description>Subjects Treated with Antiarrhythmic Drug Initiation as Randomized</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 18.1">Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cardiac sarcoidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erika Pouliot</name_or_title>
      <organization>Medtronic</organization>
      <phone>17635261270</phone>
      <email>erika.pouliot@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

